Cilostazol trial

INTERVENTION: Aspirin 81‐100mg/day Aspirin 81‐100mg/day + cilostazol 200mg/day CONDITION: peripheral arterial disease PRIMARY OUTCOME: target vessel revascularization SECONDARY OUTCOME: major adverse cardiovascular event, restenosis rate INCLUSION CRITERIA: 1)PAD patients with intermittent claudication who had a de novo femoropopliteal disease without an inflow lesion (aortoiliac or common femoral lesion), with an outflow artery (below the knee arteries) with more than one vessel run‐off, and with symptoms that were not improved by pharmacotherapy or exercise therapy 2) ankle‐brachial index (ABI) of ≤ 0.9 3) a percentage stenosis diameter of ≥ 50% by visual estimate on angiography